• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Topics » Private » Series C

Series C
Series C RSS Feed RSS

White Euro symbol on blue background

Catalym closes $51M series C round to accelerate visugromab development

Nov. 22, 2022
By Cormac Sheridan
Catalym GmbH raised €50 million (US$51.3 million) in a series C round to expand and accelerate phase IIa development of visugromab (CTL-002), a first-in-class growth differentiation factor 15 inhibitor, across a range of solid tumor indications.
Read More
Gold dollar sign

Jnana closes $107M series C round, banks $50M up front in second discovery Roche pact

Nov. 15, 2022
By Cormac Sheridan
Momentum is building at Jnana Therapeutics Inc. The firm has raised $107 million in a series C round and banked another $50 million up front from a new drug discovery and development pact with Roche Holding AG, which could potentially deliver significant near-term milestones and more than $2 billion in future milestone payments. It also commenced recruitment onto a first-in-human study of its lead drug candidate, JNT-517, an inhibitor of the phenylalanine transporter SLC6A19, which is in development for phenylketonuria.
Read More
Hand holding dollar sign

Osler raises $85M as it embarks on bid for regulator approvals

Nov. 14, 2022
By Nuala Moran
Osler Diagnostics Ltd. has raised $85 million in a series C round, as it embarks on clinical testing to secure regulatory approvals for its portable central lab quality diagnostics system.
Read More

Maxinovel raises ¥100M in series C+ financing

Oct. 25, 2022
By Doris Yu
Maxinovel Pharmaceuticals Inc. raised ¥100 million (US$13.8 million) in a series C+ round to develop its candidates for acute myeloid leukemia, solid tumors, and autoimmune diseases.
Read More
Yen-Yuan currency symbol

Maxinovel raises ¥100M in series C+ financing

Oct. 24, 2022
By Doris Yu
Maxinovel Pharmaceuticals Inc. raised ¥100 million ($13.8 million) in a series C+ round to develop its candidates for acute myeloid leukemia, solid tumors, and autoimmune diseases.
Read More
Genetesis

Genetesis closes $17.5M fundraising round for Cardioflux imaging system

Oct. 7, 2022
By Annette Boyle
Genetesis Inc. nearly doubled its total funds raised to $40 million with a $17.5 million series C financing round to support new clinical trials and commercialize its magnetocardiography system, Cardioflux. Mithril Capital led the round with participation from another new investor, Cercano Management, as well existing investors Jobs Ohio Growth Capital, Ohio Innovation Fund and Cincytech.
Read More
Human cell illustration

Cellarity adds $121M in series C to look beyond targets in cell-centric approach

Oct. 4, 2022
By Jennifer Boggs
At first glance, Cellarity Inc. might appear as one more company harnessing the computational power of AI and machine learning to boost drug discovery efforts. A closer look, however, reveals a different approach, one that looks at cells and cellular behavior to address disease rather than the traditional method of seeking out molecular targets.
Read More
tricuspid regurgitation

Tricares closes $47M for development of Topaz valve for tricuspid regurgitation

Sep. 21, 2022
By Bernard Banga
Tricares SAS raised $47 million in a first closing of its series C financing to fund further development of Topaz, its minimally invasive treatment for tricuspid regurgitation. The completion of the series C financing round is expected later in 2022.
Read More
Moximed Misha knee implant

Investors inject $40M into new osteoarthritis implant

Aug. 17, 2022
By Catherine Longworth
Moximed Inc. has received $40 million in series C financing to pursue regulatory approval for its implantable shock absorber (ISA) for knee osteoarthritis (OA). Fremont, Calif.-based Moximed secured backing from investors including Advent Life Sciences, New Enterprise Associates, Future Fund, Vertex Healthcare and Runway Growth Capital to advance the Misha knee system. The company is touting the technology as the world’s first implantable shock absorber for OA.
Read More
Illustration of doctor using surgical robot on patient

Levita lines up $26M for magnetic robot platform

Aug. 11, 2022
By Catherine Longworth
Investors are backing Levita Magnetics International Corp. with $26 million to advance its new Magnetic-Assisted Robotic Surgery (MARS) platform. The series C financing round was led by Ballast Capital, with participation from Medtex Ventures, Invermaster and Carao Ventures. The new platform builds on the company’s first commercial device, the Levita Magnetic Surgical system which received U.S. FDA approval in 2015. The system enables reduced-port laparoscopic surgical procedures and consists of an external magnet that is placed on the skin and controls a magnetic grasper inside the abdomen during surgery.
Read More
Previous 1 2 3 4 5 6 7 8 9 10 … 18 19 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 18, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 18, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 17, 2025
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe